Market narrative
Move between stock news, official company releases, crypto, and FX without losing the path back to ticker research.
Same-Restaurant Sales Growth of 3.4% Total revenues increased 15.2% Net income of $2.3 million and Adjusted EBITDA of $34.5 million 18 new System-wide restaurants opened in 15 states
Press releases
DISA Uranium Receives US$105 million in Financing Commitments, Backed by Consortium of Leading Strategic Investors TORONTO, Aug. 4, 2026 /PRNewswire/ -- IsoEnergy Ltd. ("IsoEnergy") (NYSE American: ISOU) (TSX: ISO) is pleased to announce that it has entered into a definitive agreement with DISA Technologies, Inc. ("DISA") to create DISA Uranium™ Corporation ("DISA Uranium" or the "Company"), a new technology-enabled U.S. uranium company positioned to strengthen domestic uranium supply and support the growing demand for secure, U.S.-sourced nuclear fuel.
Fiscal Year 2026 Recurring revenues grew 8% on a reported and constant currency basis Diluted EPS was $9.60 and Adjusted EPS grew 12% to $9.60 Closed sales rose to $305 million Raising annual dividend by 12% to $4.36, 20th consecutive annual dividend increase Fiscal year 2027 guidance calls for 6-8% Recurring revenue growth constant currency and 8-12% Adjusted EPS growth NEW YORK, Aug. 4, 2026 /PRNewswire/ -- Broadridge Financial Solutions, Inc. (NYSE:BR) today reported financial results for the fourth quarter and fiscal year 2026. Results compared with the same period last year were as follows: Summary Financial Results Fourth Quarter Fiscal Year Dollars in millions, except per share data 2026 2025 Change 2026 2025 Change Recurring revenues $1,542 $1,424 8 % $4,878 $4,508 8 % Constant currency growth (Non-GAAP) 8 % 8 % Total revenues $2,220 $2,065 7 % $7,477 $6,889 9 % Operating income $546 $499 10 % $1,301 $1,189 9 % Margin 24.6 % 24.1 % 17.4 % 17.3 % Adjusted Operating income (Non-GAAP) $598 $558 7 % $1,535 $1,411 9 % Margin (Non-GAAP) 26.9 % 27.0 % 20.5 % 20.5 % Diluted EPS $3.44 $3.16 9 % $9.60 $7.10 35 % Adjusted EPS (Non-GAAP) $3.82 $3.55 8 % $9.60 $8.55 12 % Closed sales $158 $114 39 % $305 $288 6 % "Broadridge is delivering strong results today while positioning our company for an exciting digital, agentic, and tokenized future," said Tim Gokey, Broadridge's CEO.
Revenue increased 60.7% year-over-year to $72.5 million in Q2 2026 Clinical revenue increased 22.6% sequentially in Q2 2026; Excluding Clinical acquisitions that closed in Q2 2026, Clinical revenue increased 15.1% sequentially driven by a 23.8% increase in Transplant Clinical revenue Q2 2026 net loss from continuing operations of $(10.5) million or (14.5)% of revenue Adjusted EBITDA (1) of $7.9 million in Q2 2026; Adjusted EBITDA margin of 10.9% Cash flow from operating activities was $5.7 million in Q2 2026; Free Cash Flow (1) was $2.9 million in Q2 2026 Completed bolt-on acquisitions of Louisville Perfusion Services, Heart and Lung Transplant National Recovery Program and Ohio Valley Perfusion Associates during Q2 2026 Signed agreement to take over Statline's Transplant Center Organ Placement customer relationships on a rolling basis over the next year NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, "Strata" or the "Company"), today announced financial results for the second quarter ended June 30, 2026. Financial results in this release, including all comparisons to prior year periods, reflect continuing operations only.
NASHVILLE, Tenn., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will report second quarter 2026 financial results after the market closes on Monday, August 10, 2026.
THE WOODLANDS, Texas, Aug. 04, 2026 (GLOBE NEWSWIRE) -- LGI Homes, Inc. (NASDAQ: LGIH) today announced financial results for the second quarter and the six months ended June 30, 2026. “We delivered strong results during the second quarter, exceeding expectations across key metrics while navigating a dynamic operating environment,” said Eric Lipar, Chairman and Chief Executive Officer of LGI Homes.
– Secured the first-ever regulatory approval of a PROTAC (a type of heterobifunctional protein degrader ), VEPPANU, and successfully completed out-licensing to Rigel Pharmaceuticals – – Anticipates sharing clinical data from three Phase 1 programs - ARV-393, ARV-102 and ARV-027 - over the next 12 months – – Presented promising preclinical data for HPK1 degrader program (ARV-6723) demonstrating the potential to overcome immune checkpoint inhibitor resistance in solid tumors – – Company to host conference call today at 8:00 a.m. ET – NEW HAVEN, Conn.
LONDON, ON, Aug. 4, 2026 /PRNewswire/ -- VersaBank ("VersaBank" or the "Bank") (TSX: VBNK) (NASDAQ:VBNK), a North American leader in business-to-business digital banking, as well as technology solutions for cybersecurity, today announced the appointment of investor relations veteran Lawrence Chamberlain as Global Senior Vice President, Investor and Stakeholder Relations, effective immediately. "Lawrence has played an integral role in VersaBank's investor relations program for the last six years on a consulting basis and has developed a deep understanding of our business, strategy and growth opportunities, transforming the communication of our investment thesis while increasing visibility of that thesis," said David Taylor, Founder and President, VersaBank.
Q2 Net Revenue of $3.5 billion with 21.7 million Active Customers BOSTON, Aug. 4, 2026 /PRNewswire/ -- Wayfair Inc. ("Wayfair," "we," or "our") (NYSE: W), the destination for all things home, today reported financial results for its second quarter ended June 30, 2026. Second Quarter 2026 Financial Highlights Total net revenue of $3.5 billion, increased $246 million, up 7.5% year over year U.S. net revenue of $3.1 billion, increased $251 million, up 8.7% year over year International net revenue of $394 million, decreased $5 million, down 1.3% year over year.
Toronto, Ontario--(Newsfile Corp. - August 4, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce that it has engaged Global One Media Group Pte. Ltd. ("Global One Media") to provide digital investor marketing and communications services to the Company.
First FDA-approved IHC assay identifies patients who may be eligible for combination treatment with TRUQAP® (capivasertib) BURLINGTON, N.C., Aug. 4, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced the nationwide availability of Roche's VENTANA® PTEN (SP218) RxDx Assay, the first immunohistochemistry (IHC) companion diagnostic test approved by the U.S. Food and Drug Administration (FDA) to determine PTEN protein loss, also known as PTEN deficiency, in tumors of patients with prostate adenocarcinoma.
SINGAPORE, Aug. 04, 2026 (GLOBE NEWSWIRE) -- TOP Financial Group Limited (NASDAQ: TOP, “TOP” or the “Company”), a fast-growing online brokerage firm specializing in local and foreign equities, futures, and options products, today announced that its Board of Directors has approved a major strategic initiative to expand the use of artificial intelligence (AI) across its core financial business. Under this new technical mandate, the Company will develop and deploy advanced AI solutions designed to create scalable, technology-driven business lines while directly supporting and optimizing its core fintech operations.
Northvale, New Jersey--(Newsfile Corp. - August 4, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, today announced that the company has launched Elite's generic version of Requip XL® (Ropinirole Extended-Release Tablets USP), with strengths of 2 mg, 4 mg, 6 mg, 8 mg, and 12 mg tablets. Ropinirole belongs to a class of drugs known as a non-ergoline dopamine agonist used to treat Parkinson's disease.
SAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced the appointment of Molly Carr, M.D., as Chief Medical Officer, further strengthening its executive leadership as the company advances its clinical-stage cardiometabolic pipeline. An experienced physician with over 30 years of clinical, academic and biopharmaceutical experience in endocrinology and metabolic disease, Dr. Carr will lead the company's global clinical strategy, medical affairs, and regulatory initiatives as it advances its pipeline toward late-stage development.
ATS296X-series combines Actions' latest wireless audio technology with Ceva's Bluetooth® High DataThroughput platform, extending a collaboration that has delivered more than 100 million wireless audio SoCs ROCKVILLE, Md. and ZHUHAI, China, Aug. 4, 2026 /PRNewswire/ -- Ceva, Inc. (NASDAQ: CEVA), the leading licensor of silicon and software IP for the Smart Edge, and Actions Technology Co., Ltd.
Toronto, Ontario--(Newsfile Corp. - August 4, 2026) - Delta Resources Limited (TSXV: DLTA) (OTCQB: DTARF) (FSE: 6GO1) ("Delta" or "the Company") is pleased to announce the commencement of its 2026 till sampling program at its flagship Delta-1 Gold Project, located approximately 50 kilometres west of Thunder Bay, Ontario. The 2026 program is designed to complete the remaining southeastern portion of the property, including claims acquired in 2024, bringing geochemical till coverage to near-complete coverage of the entire Delta-1 land package.
Black Pearl Data Center Delivery Accelerated Acquired Option for 900 MW Site Near San Antonio, Texas Completed Project-Level Financing to Fully Fund Third Data Center Development NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Cipher Digital Inc. (NASDAQ: CIFR) (“Cipher” or the “Company”), a leading developer, owner, and operator of industrial-scale data centers, today announced its second quarter 2026 financial results, with an update on its operations and business strategy. As part of this update, Cipher disclosed an amendment to its Black Pearl campus lease with its investment-grade hyperscale tenant, accelerating the development timeline of initial capacity at the tenant's request.
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today financial results for the second quarter ended June 30, 2026. Second Quarter Business Highlights Completed its first full quarter under the Company's exclusive capitated agreement with a large national integrated delivery networ.
SEATTLE--(BUSINESS WIRE)--Gravitics, Inc., an orbital infrastructure company, today announced it has been selected to support Lockheed Martin in the execution of a U.S. Department of War contract of national importance. “Being selected to support Lockheed Martin's team is a meaningful milestone for Gravitics,” said Michael Bowker, Chief Business Officer at Gravitics. “Our focus is on disciplined execution for partners working on critical national security priorities. We are proud to work with L.
ATLANTA--(BUSINESS WIRE)--Angel Oak Mortgage REIT, Inc. (NYSE: AOMR) (the “Company,” “we,” and “our”), a leading real estate finance company focused on acquiring and investing in first and second lien non-QM loans and other mortgage-related assets in the U.S. mortgage market, today reported financial results for the quarter ended June 30, 2026. Second Quarter and Year to Date 2026 Highlights Q2 2026 GAAP net income of $3.4 million, or $0.14 per diluted share of common stock. Q2 2026 net interes.
